Stockscreener 앱 받기
11.71
14.96%
-2.06
시간 외 거래:
11.65
-0.06
-0.51%
Keros Therapeutics Inc 주식(KROS)의 최신 뉴스
Wells Fargo & Company Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $20.00 - MarketBeat
Wells Fargo Maintains "Overweight" on Keros Therapeutics (KROS), Lowers Price Target | KROS Stock News - GuruFocus
Keros Therapeutics Reports FY25 Results, Highlights Progress Across Hematology And Muscle Pipeline - Nasdaq
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates - Bitget
Keros Therapeutics (NASDAQ: KROS) lands $200M Takeda deal and advances TGF-ß pipeline - Stock Titan
Keros Therapeutics (NASDAQ: KROS) swings to 2025 profit on Takeda license windfall - Stock Titan
Keros Highlights Rinvatercept Strategy in Updated Investor Presentation - TipRanks
Keros Therapeutics (NASDAQ:KROS) Posts Earnings Results, Misses Estimates By $0.37 EPS - MarketBeat
Biotech behind new DMD and ALS trials turns 2024 loss into 2025 profit - Stock Titan
KROS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ADAR1 Issues Open Letter to Keros Board, Encouraging Constructive Dialogue on Strategy, Capital Allocation, and Board Renewal - Intellectia AI
Keros Therapeutics Touts Rinvatercept DMD Trial Start, Eyes ALS Phase II Talks at Oppenheimer Conference - Yahoo Finance
Trading the Move, Not the Narrative: (KROS) Edition - Stock Traders Daily
Keros Therapeutics, Inc. (KROS) Investor Outlook: Exploring The 53% Potential Upside - DirectorsTalk Interviews
Keros Therapeutics, Inc. $KROS is Western Standard LLC's Largest Position - MarketBeat
Keros Therapeutics Adds Veteran Finance Leader to Board - TipRanks
Keros Therapeutics adds former Lyell CFO to board - Investing.com
Keros Therapeutics (KROS) CEO awarded 317,000 stock options with vesting hurdles - Stock Titan
Keros Therapeutics (KROS) CFO receives 60,000-share stock option grant - Stock Titan
Keros Therapeutics (KROS) awards Chief Legal Officer 80,000 options - Stock Titan
Keros Therapeutics (NASDAQ: KROS) grants CSO 75,000 options - Stock Titan
Ex-Lyell CFO and healthcare banker Charles Newton joins Keros board - Stock Titan
KROS Technical Analysis & ETF Price Forecast - Intellectia AI
Keros Therapeutics, Inc. (KROS) Investor Outlook: Analyzing a 38.97% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Keros Therapeutics (KROS) CEO auto-sells 7,015 shares for tax withholding - Stock Titan
Can Keros Therapeutics Inc. reach resistance levels soonJuly 2025 Outlook & Verified Swing Trading Watchlists - mfd.ru
Risk Hedge: What is the next catalyst for Keros Therapeutics IncQuarterly Portfolio Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Portfolio Update: Is now the right time to enter Keros Therapeutics IncJuly 2025 Movers & Low Risk Growth Stock Ideas - baoquankhu1.vn
Keros Therapeutics CEO to Present at Multiple Conferences - The Globe and Mail
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - The Manila Times
Keros Therapeutics CEO to Present at Oppenheimer, TD Cowen and Leerink Conferences - TradingView
Keros Therapeutics (NASDAQ: KROS) lines up CEO talks at key conferences - Stock Titan
Sentiment Recap: Can Keros Therapeutics Inc weather a recessionQuarterly Trade Review & Weekly Stock Performance Updates - baoquankhu1.vn
Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? - TradingView
Keros Therapeutics (KROS) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Tang Capital reports 0% stake in Keros Therapeutics (NASDAQ: KROS) - Stock Titan
D. E. Shaw group discloses 3.9% Keros Therapeutics (KROS) ownership in 13G/A - Stock Titan
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Will Keros Therapeutics Inc. stock keep outperforming rivalsQuarterly Market Review & Community Verified Trade Alerts - mfd.ru
Can Keros Therapeutics Inc. reach all time highs this yearJuly 2025 Analyst Calls & Safe Capital Growth Stock Tips - mfd.ru
Keros Therapeutics, Inc. (KROS) Stock Analysis: Spotlight on a 37.72% Potential Upside in Biotech - DirectorsTalk Interviews
Is Keros Therapeutics Inc. likely to announce a buybackMarket Performance Summary & Free Fast Entry Momentum Trade Alerts - mfd.ru
Why Keros Therapeutics Inc. stock could see breakout soon2025 Market Sentiment & Smart Allocation Stock Tips - mfd.ru
What analyst consensus says on Keros Therapeutics Inc. stockQuarterly Growth Report & Safe Entry Momentum Tips - mfd.ru
How much upside does Keros Therapeutics Inc. haveWeekly Trading Summary & Real-Time Buy Signal Alerts - mfd.ru
Keros Therapeutics: Key Catalysts and Financial Runway in Focus - AD HOC NEWS
Price-Driven Insight from (KROS) for Rule-Based Strategy - Stock Traders Daily
How Keros Therapeutics Inc. stock benefits from global expansion2025 Fundamental Recap & Reliable Entry Point Trade Alerts - mfd.ru
Y Intercept Hong Kong Ltd Lowers Holdings in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics, Inc. $KROS Shares Sold by Federated Hermes Inc. - MarketBeat
Big Picture: What is SIDUs revenue forecastGap Up & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Risk Report: What is the next catalyst for Keros Therapeutics IncDividend Hike & High Accuracy Trade Alerts - baoquankhu1.vn
Tech Rally: Is CleanCore Solutions Incs ROE strong enough2025 Stock Rankings & Risk Managed Trade Strategies - baoquankhu1.vn
Aug Opening: Will HUB Cyber Security Ltd. Equity Warrant outperform during market ralliesJuly 2025 WrapUp & Target Return Focused Stock Picks - baoquankhu1.vn
Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? - Nasdaq
Portfolio Shifts: Can NECB benefit from deglobalizationJuly 2025 Reactions & Community Driven Trade Alerts - baoquankhu1.vn
Market Wrap: What is the next catalyst for Keros Therapeutics IncAnalyst Downgrade & Capital Efficiency Focused Ideas - baoquankhu1.vn
Is KROS' KER-065 the Next Breakthrough in DMD Space? - The Globe and Mail
3.69%
0.68%
자본화:
|
볼륨(24시간):